Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a Study of HC022 in Healthy Subjects
NCT06657703Phase 1Recruiting
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HC022 in systemic lupus erythematosus (SLE) (5 arms). Primary endpoint: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 20 weeks. Started Nov 2024; status: recruiting.
02
Drugs
HC022
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06657703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657703.